Concussions Market: Information by Treatment (Diagnosis and Treatment) by End User (Hospitals and Clinics, Diagnostic Centers and Payers) & Region - Global Forecast till 2027
ID: MRFR/Pharma/4269-CR | July 2019 | Region: Global | 145 pages
The Global Concussions Market is expected to register a CAGR of 3.22% to reach USD 1,060.36 Million by 2023. A concussion is a mild traumatic brain injury that disrupts the normal function of the brain temporarily. Concussions are generally caused by a blow or jolt to the head. However, it can occur from a hit to the body that produces a reflex force to the head. Concussions are majorly seen in falls, sports, and car crashes.
Increasing incidence of mild traumatic brain injuries, ongoing product development, and approval growing geriatric population are expected to enhance the market growth. However, factors such as stringent regulatory framework and shortage of trained professionals restrain the growth of the market during the forecast period.
Market Dynamics
The global Concussions market has been primarily driven by increasing incidence of mild traumatic brain injuries, ongoing product development, and approval growing the geriatric population. According to recent research conducted by the University of Pittsburgh’s Brain Trauma Research Center, over 62,000 concussion injuries are sustained in high school contact sports every year in the US. Furthermore, according to the World Health Organization (WHO), the global incidence for TBI is close to 10 million people annually. Therefore, the increasing prevalence of mild traumatic injuries is expected to provide favorable backgrounds for the market to grow over the forecast period. Factors such as stringent regulatory framework, shortage of trained professionals are restraining the growth of the market in the forecast period.
Global Concussions Market Revenue, by, 2017 & 2023 (USD Million) 
Sources: MRFR Analysis
Segmentation
The global concussions market has been bifurcated into treatment and end user. Based on treatment, the market is classified as diagnosis and treatment. Diagnosis segment held a market share of 818.09 USD Million in 2017. On the basis of the end user, the concussion market has been divided into hospital and clinics, diagnostic centers, and payers.
Asia-Pacific Concussions Market Share, 2017(%) 
Sources: MRFR Analysis
Regional Analysis
The global concussions market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to be the most significant global concussions market. This can be attributed to the increase in the cases of concussion. Moreover, the growing awareness created by several government organizations as well as private firms is fueling the growth of the market in the region.
The European market for concussions is expected to be the second-largest global concussions market. The rising incidence rate of concussions helps to boost the growth of the market.
Asia-Pacific is estimated to be the fastest-growing market owing to the developing healthcare infrastructure and increasing disposable income. The rise in the improved healthcare infrastructure promises a high level of research activities in the region. Moreover, the increase in the setups of research and development centers boosts the growth of this market. The increase in traumatic brain injuries has also boosted the growth of the market in this region. Japan held a market share of 19.3% in 2017.
The Middle East & Africa is expected to witness steady growth due to limited access and healthcare affordability among the population. Rising awareness regarding health and availability of new treatment and diagnostic methods are expected to drive the market in this region. Moreover, a high number of traumatic brain injuries occurring in this region indirectly boosts the growth of the market.
Key Players
The prominent players in the global concussions market are Teva Pharmaceutical Industries Ltd, Integra LifeSciences Corporation, Medtronic PLC, Sun Pharmaceutical Industries Ltd, Lupin, Zydus Cadila, Pfizer, Inc., Mylan NV, Novartis AG, Sanofi SA.
The players operating in the global concussions market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
- In October 2016, Teva Pharmaceutical Industries Ltd Teva acquired Anda, Inc., a leading distributor of generic pharmaceuticals in the US from Allergan PLC.
- In November 2018, Sun Pharma acquired Pola Pharma, which is into R&D, manufacturing, and sales and distribution of branded and generic products in Japan.
- In July 2018, Lupin received the UK Medicine’s and Healthcare Products Regulatory Agency (MHRA) approval for its Goa facility.
Market Segmentation
Global Concussions Market, by Diagnosis and Treatment
- Diagnosis
- Treatment
Global Concussions Market, by End User
- Hospitals and Clinics
- Diagnostic Centers
- Payers
Global Concussions Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Company Profiles of Other Key Players
- Zimmer Biomet
- Neuren Pharmaceuticals Ltd
- Oxygen Biotherapeutics, Inc.
- Challenges in Concussion Market
- Investment Opportunities in the Concussions Market
Intended Audience
- Pharmaceuticals manufacturers
- Healthcare providers
- Research institutes and academic centers
- Government associations
- Market research and consulting
Frequently Asked Questions (FAQ) :
The global concussions market is predicted to touch USD 1,060.36 million by 2023.
The concussions market is predicted to grow at a 3.22% CAGR between 2020-2027.
The Americas is projected to lead the concussions market during the forecast period.
Ongoing product development, increasing prevalence of mild traumatic brain injuries, and improved healthcare infrastructure are adding to the market growth.
Lack of trained professionals and strict regulatory framework may limit market growth.
1 Executive Summary
2 Market Introduction
2.1 Definition 18
2.2 Scope of the Study 18
2.3 Market Structure 18
3 Research Methodology
3.1 Research Process 19
3.2 Primary Research 20
3.3 Secondary Research 21
3.4 Market Size Estimation 22
3.5 Forecast Model 22
4 Market Dynamics
4.1 Overview 23
4.2 Drivers 23
4.2.1 Increasing Incidence of Mild Traumatic Brain Injuries 24
4.2.2 Ongoing Product Development and Approval 24
4.2.3 Growing Geriatric Population 24
4.3 Restraints 25
4.3.1 Stringent Regulatory Framework 25
4.3.2 Shortage of Trained Professionals 25
4.4 Opportunities 25
4.4.1 Growing Awareness about Concussions 25
5 Market Factor Analysis
5.1.1 R&D and Designing 26
5.1.2 Manufacturing 26
5.1.3 Distribution & Sales 27
5.1.4 Post-Sales Services 27
5.2 Porter’s Five Forces Analysis 27
5.2.1 Bargaining Power of Suppliers 28
5.2.2 Bargaining Power of Buyers 28
5.2.3 Threat of New Entrants 28
5.2.4 Threat of Substitutes 28
5.2.5 Intensity of Rivalry 28
5.3 Investment Opportunities 29
5.4 Pricing Analysis 29
6 Global Concussions Market by Diagnosis & Treatment
6.1 Overview 30
6.2 Diagnosis 31
6.3 Treatment 33
7 Global Concussions Market, by End User
7.1 Overview 35
7.2 Hospitals and Clinics 36
7.3 Diagnostic Centers 37
7.4 Payers 37
8 Global Concussions Market, by Region
8.1 Overview 38
8.2 Americas 40
8.2.1 North America 43
8.2.1.1 US 45
8.2.1.2 Canada 47
8.2.2 Latin America 49
8.3 Europe 51
8.3.1 Western Europe 53
8.3.1.1 Germany 56
8.3.1.2 France 57
8.3.1.3 UK 59
8.3.1.4 Italy 61
8.3.1.5 Spain 62
8.3.1.6 Rest of Western Europe 64
8.3.2 Eastern Europe 66
8.4 Asia-Pacific 68
8.4.1 China 71
8.4.2 Japan 73
8.4.3 India 74
8.4.4 Australia 76
8.4.5 South Korea 78
8.4.6 Rest of Asia-Pacific 80
8.5 Middle East & Africa 82
8.5.1 Middle East 85
8.5.2 Africa 87
9 Competitive Landscape
9.1 Competitive Scenario 89
9.2 Prominent Players in the Concussion Therapeutics Industry 89
9.3 Prominent Players in the Concussion Diagnostic Industry 90
9.4 Key Developments 91
10 Company Profile
10.1 Teva Pharmaceutical Industries Ltd 94
10.1.1 Company Overview 94
10.1.2 Financial Overview 94
10.1.3 Products/Services Offered 95
10.1.4 Key Developments 95
10.1.5 SWOT Analysis 95
10.1.6 Key Strategies 96
10.2 Integra LifeSciences Corporation 97
10.2.1 Company Overview 97
10.2.2 Financial Overview 97
10.2.3 Products Offering 98
10.2.4 Key Developments 98
10.2.5 SWOT Analysis 98
10.2.6 Key Strategies 98
10.3 Medtronic PLC 99
10.3.1 Company Overview 99
10.3.2 Financial Overview 99
10.3.3 Products Offering 100
10.3.4 Key Developments 100
10.3.5 SWOT Analysis 100
10.3.6 Key Strategies 100
10.4 Sun Pharmaceutical Industries Ltd 101
10.4.1 Company Overview 101
10.4.2 Financial Overview 101
10.4.3 Products/Services Offered 102
10.4.4 Key Developments 102
10.4.5 SWOT Analysis 103
10.4.6 Key Strategies 103
10.5 Lupin 104
10.5.1 Company Overview 104
10.5.2 Financial Overview 104
10.5.3 Products/Services Offered 105
10.5.4 Key Developments 105
10.5.5 SWOT Analysis 106
10.5.6 Key Strategies 106
10.6 Zydus Cadila 107
10.6.1 Company Overview 107
10.6.2 Financial Overview 107
10.6.3 Products/Services Offered 108
10.6.4 Key Developments 108
10.6.5 SWOT Analysis 108
10.6.6 Key Strategies 108
10.7 Pfizer, Inc. 109
10.7.1 Company Overview 109
10.7.2 Financial Overview 109
10.7.3 Products/Services Offered 110
10.7.4 Key Developments 110
10.7.5 SWOT Analysis 110
10.7.6 Key Strategies 110
10.8 Mylan NV 111
10.8.1 Company Overview 111
10.8.2 Financial Overview 111
10.8.3 Products/Services Offered 112
10.8.4 Key Developments 112
10.8.5 SWOT Analysis 112
10.8.6 Key Strategies 112
10.9 Novartis AG 113
10.9.1 Company Overview 113
10.9.2 Financial Overview 113
10.9.3 Products/Services Offered 114
10.9.4 Key Developments 114
10.9.5 SWOT Analysis 114
10.9.6 Key Strategies 114
10.10 Sanofi SA 115
10.10.1 Company Overview 115
10.10.2 Financial Overview 115
10.10.3 Products/Services Offered 116
10.10.4 Key Developments 116
10.10.5 SWOT Analysis 116
10.10.6 Key Strategies 116
11 Appendix
11.1 References 117
11.2 Related Reports 117
12 List of Tables
TABLE 1 GLOBAL CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 31
TABLE 2 GLOBAL CONCUSSIONS MARKET FOR DIAGNOSIS, BY REGION, 2020–2027 (USD MILLION) 32
TABLE 3 GLOBAL CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 32
TABLE 4 GLOBAL CONCUSSIONS MARKET FOR TREATMENT, BY REGION, 2020–2027 (USD MILLION) 33
TABLE 5 GLOBAL CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 34
TABLE 6 GLOBAL CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 36
TABLE 7 GLOBAL CONCUSSIONS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2020–2027 (USD MILLION) 36
TABLE 8 GLOBAL CONCUSSIONS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 37
TABLE 9 GLOBAL CONCUSSIONS MARKET FOR PAYERS, BY REGION, 2020–2027 (USD MILLION) 37
TABLE 10 GLOBAL CONCUSSIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 39
TABLE 11 AMERICAS: CONCUSSIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 41
TABLE 12 AMERICAS: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 41
TABLE 13 AMERICAS: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 41
TABLE 14 AMERICAS: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 42
TABLE 15 AMERICAS: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 42
TABLE 16 NORTH AMERICA: CONCUSSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 43
TABLE 17 NORTH AMERICA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 44
TABLE 18 NORTH AMERICA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 44
TABLE 19 NORTH AMERICA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 44
TABLE 20 NORTH AMERICA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 45
TABLE 21 US: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 45
TABLE 22 US: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 45
TABLE 23 US: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 46
TABLE 24 US: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 46
TABLE 25 CANADA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 47
TABLE 26 CANADA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 47
TABLE 27 CANADA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 48
TABLE 28 CANADA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 48
TABLE 29 LATIN AMERICA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 49
TABLE 30 LATIN AMERICA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 49
TABLE 31 LATIN AMERICA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 50
TABLE 32 LATIN AMERICA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 50
TABLE 33 EUROPE: CONCUSSIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 51
TABLE 34 EUROPE: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 52
TABLE 35 EUROPE: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 52
TABLE 36 EUROPE: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 52
TABLE 37 EUROPE: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 53
TABLE 38 WESTERN EUROPE: CONCUSSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54
TABLE 39 WESTERN EUROPE: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 54
TABLE 40 WESTERN EUROPE: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 54
TABLE 41 WESTERN EUROPE: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 55
TABLE 42 WESTERN EUROPE: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 55
TABLE 43 GERMANY: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 56
TABLE 44 GERMANY: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 56
TABLE 45 GERMANY: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 56
TABLE 46 GERMANY: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 57
TABLE 47 FRANCE: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 57
TABLE 48 FRANCE: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 57
TABLE 49 FRANCE: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 58
TABLE 50 FRANCE: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 58
TABLE 51 UK: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 59
TABLE 52 UK: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 59
TABLE 53 UK: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 59
TABLE 54 UK: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 60
TABLE 55 ITALY: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 61
TABLE 56 ITALY: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 57 ITALY: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 58 ITALY: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 62
TABLE 59 SPAIN: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 62
TABLE 60 SPAIN: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 63
TABLE 61 SPAIN: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 63
TABLE 62 SPAIN: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 63
TABLE 63 REST OF WESTERN EUROPE: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 64
TABLE 64 REST OF WESTERN EUROPE: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 64
TABLE 65 REST OF WESTERN EUROPE: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 65
TABLE 66 REST OF WESTERN EUROPE: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 65
TABLE 67 EASTERN EUROPE: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 66
TABLE 68 EASTERN EUROPE: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 66
TABLE 69 EASTERN EUROPE: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 66
TABLE 70 EASTERN EUROPE: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 67
TABLE 71 ASIA-PACIFIC: CONCUSSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 69
TABLE 72 ASIA-PACIFIC: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 69
TABLE 73 ASIA-PACIFIC: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 74 ASIA-PACIFIC: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 75 ASIA-PACIFIC: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 70
TABLE 76 CHINA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 71
TABLE 77 CHINA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 71
TABLE 78 CHINA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 72
TABLE 79 CHINA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 72
TABLE 80 JAPAN: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 73
TABLE 81 JAPAN: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 73
TABLE 82 JAPAN: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 73
TABLE 83 JAPAN: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 74
TABLE 84 INDIA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 74
TABLE 85 INDIA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 75
TABLE 86 INDIA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 75
TABLE 87 INDIA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 75
TABLE 88 AUSTRALIA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 76
TABLE 89 AUSTRALIA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 76
TABLE 90 AUSTRALIA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 91 AUSTRALIA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 77
TABLE 92 SOUTH KOREA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 78
TABLE 93 SOUTH KOREA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 94 SOUTH KOREA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 95 SOUTH KOREA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 79
TABLE 96 REST OF ASIA-PACIFIC: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 80
TABLE 97 REST OF ASIA-PACIFIC: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 80
TABLE 98 REST OF ASIA-PACIFIC: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 99 REST OF ASIA-PACIFIC: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 81
TABLE 100 MIDDLE EAST & AFRICA: CONCUSSIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 101 MIDDLE EAST & AFRICA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 83
TABLE 102 MIDDLE EAST & AFRICA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 83
TABLE 103 MIDDLE EAST & AFRICA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 104 MIDDLE EAST & AFRICA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 84
TABLE 105 MIDDLE EAST: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 85
TABLE 106 MIDDLE EAST: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 107 MIDDLE EAST: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 108 MIDDLE EAST: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 86
TABLE 109 AFRICA: CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 87
TABLE 110 AFRICA: CONCUSSIONS MARKET FOR DIAGNOSIS, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 111 AFRICA: CONCUSSIONS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 112 AFRICA: CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 88
TABLE 113 MAJOR PLAYERS IN THE CONCUSSION DIAGNOSTIC MARKET 90
TABLE 114 GLOBAL CONCUSSION MARKET: KEY DEVELOPMENT 91
13 List of Figures
FIGURE 1 MARKET SYNOPSIS 15
FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL CONCUSSIONS MARKET 16
FIGURE 3 GLOBAL CONCUSSIONS MARKET SHARE, BY DIAGNOSIS AND TREATMENT, 2020 (%) 16
FIGURE 4 GLOBAL CONCUSSIONS MARKET BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 17
FIGURE 5 GLOBAL CONCUSSIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 17
FIGURE 6 GLOBAL CONCUSSIONS MARKET BY END USER, 2020–2027 (USD MILLION) 17
FIGURE 7 GLOBAL CONCUSSIONS MARKET: MARKET STRUCTURE 18
FIGURE 8 RESEARCH PROCESS OF MRFR 19
FIGURE 9 TOP-DOWN & BOTTOM-UP APPROACH 22
FIGURE 10 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CONCUSSIONS MARKET 23
FIGURE 11 VALUE CHAIN: GLOBAL CONCUSSIONS MARKET 26
FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: GLOBAL CONCUSSIONS MARKET 27
FIGURE 13 GLOBAL CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020 (%) 30
FIGURE 14 GLOBAL CONCUSSIONS MARKET, BY DIAGNOSIS & TREATMENT, 2020 AND 2027 (USD MILLION) 30
FIGURE 15 GLOBAL CONCUSSIONS MARKET, BY END USER, 2020 (%) 35
FIGURE 16 GLOBAL CONCUSSIONS MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 35
FIGURE 17 GLOBAL CONCUSSIONS MARKET, BY REGION, 2020 (%) 38
FIGURE 18 GLOBAL CONCUSSIONS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 38
FIGURE 19 AMERICAS: CONCUSSIONS MARKET, BY REGION, 2020 AND 2027 40
FIGURE 20 NORTH AMERICA: CONCUSSIONS MARKET, BY COUNTRY, 2020 AND 2027 43
FIGURE 21 EUROPE: CONCUSSIONS MARKET, BY REGION, 2020 AND 2027 51
FIGURE 22 WESTERN EUROPE: CONCUSSIONS MARKET, BY COUNTRY, 2020 AND 2027 53
FIGURE 23 ASIA-PACIFIC: CONCUSSIONS MARKET, BY COUNTRY, 2020 AND 2027 68
FIGURE 24 MIDDLE EAST & AFRICA: CONCUSSIONS MARKET, BY REGION, 2020 AND 2027 82
FIGURE 25 MAJOR PLAYERS IN CONCUSSION THERAPEUTICS MARKET 89
FIGURE 26 GLOBAL CONCUSSION MARKET, COMPETITIVE LANDSCAPE (%) 93
